Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624330 | 0.84 | TSHR (0.33) | TSHRCYP2D6OPRM1OPRD1OPRK1 | |
| SCHEMBL23063614 | 0.84 | TSHR (0.43) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19504706 | 0.79 | SOS1 (0.32) | TSHRCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL18385740 | 0.77 | TSHR (0.36) | TSHRCYP2D6OPRM1CYP1A2 | |
| SCHEMBL17624099 | 0.77 | OPRM1 (0.35) | TSHRCYP3A4CYP2D6CYP2C19OPRM1 | |
| SCHEMBL22182595 | 0.77 | HIF1A (0.36) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22025563 | 0.77 | USP2 (0.33) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18202958 | 0.76 | OPRD1 (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL19498552 | 0.74 | CYP3A4 (0.33) | TSHRCYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL25001743 | 0.74 | OPRM1 (0.33) | CYP3A4CYP2D6OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | TSHR 4487/4885CYP3A4 4780/4885CYP2D6 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.